Project Grant R41HL180136
Award Date 9/20/25
Completion Date 8/31/26
Dollars Obligated $309K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
- This federal Project Grant award for $806,901.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of oxidation-specific IgA antibodies in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The research, conducted by the University of Virginia, aims to elucidate the link between B cells, IgA, and lung fibrosis in IPF, with the goal of providing insight into disease mechanisms and identifying...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $284,699 to Aqualung Therapeutics, Corp, a biotechnology company, to optimize the dosage and evaluate the efficacy of their novel ALT-100 monoclonal antibody therapy in preclinical mouse models of lung fibrosis. The goal is to demonstrate the ability of ALT-100 to slow the progression of idiopathic pulmonary fibrosis (IPF), a severe and often...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,182,827 Project Grant to Duke University to develop a 3D bioprinted alveolar sac model and dual host-microbe spatial transcriptomics technology. The goal is to enhance understanding of how the lung microbiome regulates the host response to influenza virus infection. This Allergy and Infectious Diseases Research (CFDA 93.855) program grant will fund the creation of innovative in vitro technologies to study interactions...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Oasis Pharmaceuticals, LLC a $468,369 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports the development of PAR2 pepducins, a novel class of targeted therapeutic compounds, for the treatment of chronic obstructive pulmonary disease (COPD). Oasis Pharmaceuticals is collaborating with Tufts Medical Center to advance the preclinical research and development of the PAR2...
- This federal Project Grant award, valued at $155,227.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease, which currently has no FDA-approved treatments. The strategy involves using a biofilm disruptor as an adjunct to antibiotics to more effectively...